Overview

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

Status:
Withdrawn
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Phase II, Randomized, Non-Inferiority Study Comparing an Individualized Cancer Vaccine (AlloVax™) to Chemotherapy in Subjects with R/M SCCHN .
Phase:
Phase 2
Details
Lead Sponsor:
Immunovative Therapies, Ltd.
Treatments:
Cisplatin